Your Article Summary
See Latest ArticlesTrabectedin for the management of soft-tissue sarcoma
Expert Review of Anticancer Therapy, 06/08/09
Boudou L et al. – Article outlines the therapeutic effects of Trabectedin (a new marine-derived compound that binds the DNA minor groove and interacts with proteins of the DNA-repair machinery) in the treatment of soft-tissue sarcoma and other cancers:
- Trabectedin shows promising single-agent activity in pretreated pts with soft-tissue sarcoma (STS) and ovarian and breast cancer
- Combination with various other chemotherapeutic drugs is also feasible
- Toxicities observed:
- Mainly hematological and hepatic; grade 3-4 neutropenia and thrombocytopenia observed in 50 and 20% of pts, respectively, and
- Grade 3-4 elevation of liver transaminases observed in 35-50% of pts treated with trabectedin
- Trabectedin obtained regulatory approval by the EMEA and in other countries for the treatment of STS pts after failure of all available standard-of-care chemotherapy
- Current research focuses on the identification of predictive factors for pts treated with trabectedin and development of other combination
Related Articles
Should Patients with High-Risk Soft Tissue Sarcoma Receive Adjuvant Chemotherapy
The Oncologist, 10/28/09
Relevance Score: 69%
Pathology of Soft Tissue Sarcomas
Clinical Oncology, 10/07/09
Relevance Score: 69%
Harmonizing adult and pediatric approaches to the treatment of soft-tissue sarcoma
Expert Review of Anticancer Therapy, 11/12/09
Relevance Score: 68%
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)
European Journal of Cancer, 10/29/09
Relevance Score: 68%
Skeletal metastasis from sarcoma: a report of three cases
European Journal of Orthopaedic Surgery & Traumatology, 10/23/09
Relevance Score: 68%
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Impact of anti-angiogenic treatments on metastatic renal cell carcinoma
Expert Review of Anticancer Therapy, 12/07/09
Role and rationale of gene therapy and other novel therapies in the management of NMIBC
Expert Review of Anticancer Therapy, 12/07/09
Organ-sparing strategies in the management of invasive bladder cancer
Expert Review of Anticancer Therapy, 12/07/09
Today in Soft Tissue/Sarcoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Clinical management of uterine sarcomas
The Lancet Oncology, 12/07/09
Infantile Fibrosarcoma: Management Based on the European Experience
Journal of Clinical Oncology, 12/04/09
Transformation potential of bone marrow stromal cells into undifferentiated high-grade pleomorphic sarcoma
Journal of Cancer Research & Clinical Oncology, 12/04/09